Each vial with have either 8 or 16 doses and should be a month supply.

FG peptides refer to peptides that contain phenylalanine-glycine (FG) repeat sequences, often found in proteins that act as scaffolds or transporters within cells.

The FG sequence improves peptides transport and functionality within cells while ensuring that each peptide can perform its specific function without interference from others.

FG peptides are particularly useful in precision medicine because they can be layered strategically to avoid receptor competition, allowing each peptide to target specific pathways without interfering with others.

This layering enhances the synergy of the peptides, providing more effective therapeutic outcomes.

Exosomes are small, naturally occurring vesicles that cells use for cell-to-cell communication. They act as transporters, carrying molecules such as proteins, RNA, and peptides between cells to mediate various biological processes.

Exosomes are ideal delivery vehicles for peptides because they can encapsulate therapeutic molecules, protect them from degradation, and guide them to specific cells or tissues, especially in areas of inflammation or damage.

In an exosome-based therapy, peptides are encapsulated within the exosome’s lipid bilayer. This acts like a protective bubble, ensuring the cargo safely reaches its intended target without being degraded or lost along the way.

PEGylation is a process in which a polyethylene glycol (PEG) molecule is attached to a peptide, protein, or therapeutic compound.

This modification improves the stability, solubility, half-life and circulation time of the compound in the bloodstream, helping it avoid rapid degradation and providing more sustained effects.

PEGylation enhances the bioavailability and half-life of peptides by shielding them from enzymatic degradation and reducing the immune response. This allows for longer-lasting effects with potentially fewer doses required.